A Phase 2/3 interventional study of Lactobacillus gasseri KABP®064 10e9 CFU/capsule and Placebo (maltodextrin) in Vaginosis, Bacterial, Bacterial Vaginosis and Bacterial Vaginosis (BV), sponsored by Kaneka Americas Holding Inc.. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Kaneka Americas Holding Inc. (part of Kaneka Corporation) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The vagina is a dynamic muscular organ whose health relies on a Lactobacillus-dominant microbiota that maintains low pH and protects against infections. Bacterial vaginosis (BV) is the most common vaginal imbalance in women of reproductive age, caused by depletion of protective Lactobacillus species and overgrowth of anaerobic bacteria such as Gardnerella vaginalis. BV affects an estimated 23-29 percentage of women globally (10-30 percentage in India) and is associated with discharge, odor, discomfort, and significant risks including recurrent disease, adverse reproductive outcomes, and increased susceptibility to STIs. Although antibiotics are effective for acute treatment, recurrence rates are high (50-60 percentage within 12 months), highlighting an unmet need for preventive strategies.
Probiotics, particularly Lactobacillus species, have emerged as promising options to restore vaginal microbiota balance and reduce BV recurrence. Lactobacillus gasseri is a natural vaginal commensal with antimicrobial activity against BV pathogens and the ability to lower vaginal pH. L. gasseri KABP®064 has demonstrated vaginal colonization after oral administration, good tolerability, and potential to promote vaginal health.
The present randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of oral L. gasseri KABP®064 in preventing BV recurrence over six months following standard antibiotic therapy. Outcomes include recurrence rates and timing, symptom severity, microbiological balance, inflammation markers, and patient-reported vaginal health, supporting a microbiome-focused, non-antibiotic approach to BV recurrence prevention.
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
This study's planned enrollment of 160 is above the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Browse Vaginosis, Bacterial studies →Kaneka Americas Holding Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Positive Amsel's criteria (confirming active BV) determined by at least 3 out of the following 4 symptoms or signs:
Exclusion Criteria:
Participants with substance abuse problems defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lactobacillus gasseri KABP064 in delayed-released (DR)-capsules. Strength: 1 x 10\^9 CFU/capsule
Dietary Supplement: Lactobacillus gasseri KABP®064 10e9 CFU/capsule
Placebo capsules filled with maltodextrine. Exact same appearance as active capsules.
Dietary Supplement: Placebo (maltodextrin)
Phase 1: 15 days, 1 capsule/day post-randomization. Phase 2: 10 days per month for \~6 months, starting 6th day of menstruation, 1 capsule/day.
Phase 1: 15 days, 1 capsule/day post-randomization. Phase 2: 10 days per month for \~6 months, starting 6th day of menstruation, 1 capsule/day.
To evaluate the efficacy of Lactobacillus gasseri KABP®064 in preventing recurrence of BV infections, diagnosed using Amsel criteria, over a period of 6 months as compared to placebo.
Amsel criteria (≥3 out of 4 positive)
Time frame: Day 6 to Day 180
Analysis of BV recurrences diagnosed using Nugent score (≥ 7) (main secondary endpoint)
Compared to Placebo
Time frame: Day 6 to Day 180
Analysis of BV recurrences diagnosed using both Amsel criteria (≥ 3 of 4 positive) and Nugent score (≥7)
Compared to placebo
Time frame: Day 6 to Day 180
Time to first BV recurrence as per Amsel's criteria (≥3 of 4 positive) and/or Nugent Score (≥7)
Compared to Placebo
Time frame: Day 6 to Day 180
Proportion of participants experiencing 2 or more, and 3 or more BV infections during the study period.
Compared to Placebo
Time frame: Day 6 to Day 180
Percentage of patients receiving first-line or second-line SOC and duration (days).
Compared to Placebo
Time frame: Day 6 to Day 180
Absolute difference in the duration of the SOC consumption (days).
Compared to Placebo
Time frame: Day 6 to Day 180
Reducing the duration and severity of symptoms (itching, vaginal discharge, and odor) assessed by Visual Analogue Scale (VAS).
Compared to Placebo
Time frame: Day 0, Day 6, Day 22, Day 90, Day 180, and at recurrence visits (if patients have a BV recurrence during the study time frame, they will ask for a "recurrence visit" to assess medication and some study parameters).
Percentage of patients with recovery of normal Nugent score (0-3).
Compared to Placebo
Time frame: Day 6 to Day 22
Vaginal health by International Consultation on Incontinence Questionnaire - Vaginal symptoms (ICIQ-VS).
Compared to Placebo
Time frame: Day 0, Day 6, Day 22, Day 90 and Day 180
Change in vaginal pH assessed by vaginal pH strip method.
Compared to Placebo
Time frame: Day 0, Day 6, Day 22, Day 90, Day 180, and at recurrence visits (if patients have a BV recurrence during the study time frame, they will ask for a "recurrence visit" to assess medication and some study parameters).
Concentration of proinflammatory cytokines.
Compared to Placebo
Time frame: Day 0, Day 22
Relative abundances of lactobacilli and common pathogens associated to BV assessed by using Next-Generation Sequencing (NGS).
Compared to Placebo
Time frame: Day 0, Day 6, Day 22, Day 90, Day 180
Percentage of women with vaginal Community State Types (CSTs) associated to healthy vaginal microbiota.
Compared to Placebo
Time frame: Day 0, Day 6, Day 22, Day 90, Day 180
Analysis of BV recurrences (including intermediate BV) as confirmed per Amsel criteria (≥ 3 of 4 positive) and Nugent score (score≥4) throughout the 6-month period.
Compared to Placebo
Time frame: Day 6 to Day 180
Analysis of BV recurrences (including intermediate BV) as confirmed per Nugent score (score ≥4) throughout the 6-month period.
Compared to Placebo
Time frame: Day 6 to Day 180
No study locations are listed for this record.
Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.